Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 103, Issue 20, Pages 7577-7582Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0600879103
Keywords
biopharmaceutical; glycosylation; immunogenicity
Categories
Ask authors/readers for more resources
N-glycosylation of a mAb may have a major impact on its therapeutic merits. Here, we demonstrate that expression of a hybrid enzyme (called xylGaIT), consisting of the N-terminal domain of Arabidopsis thaliana xylosyltra nsf erase and the catalytic domain of human 0-1,4-galactosyltransf erase I (GaIT), in tobacco causes a sharp reduction of N-glycans with potentially immunogenic corebound xylose (Xyl) and fucose (Fuc) residues as shown by Western blot and MALDI-TOF MS analysis. A radioallergosorbent test inhibition assay with proteins purified from leaves of WT and these transgenic tobacco plants using sera from allergic patients suggests a significant reduction of potential immunogenicity of xyl-GaIT proteins. A mAb purified from leaves of plants expressing xylGaIT displayed an N-glycan profile that featured high levels of galactose, undetectable xylose, and a trace of fucose. Hence, a transgenic plant expressing the hybrid GaIT might yield more effective and safer monoclonals for therapeutic purposes than WT plants and even transgenic plants expressing the unchanged GaIT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available